GW: We've had Pharmacyclics Inc. (PCYC) on our best ideas list at Wedbush for almost two years now, and we have a $165/share price target on it, with the stock at the $100 level or a bit higher now. We're anticipating the U.S. Food and Drug Administration [FDA] will act on its new drug application for ibrutinib [PCI-32765] shortly. Our research would suggest a potential timeframe of within 100-120 days to get an approval. That's our best idea at the moment, and we would definitely focus investors' attention on that. I think Pharmacyclics is a must-own stock. We're expecting a lot of use of ibrutinib in chronic lymphocytic leukemia [CLL], and Waldenstrom's macroglobulinemia as well, once the drug is approved.